$AMED
AMEDISYS INC Stock $amed

$amed Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000089626221000045 Filed on February 25, 2021

Income Statement

Concept	2020 Q4	2019 Q4	2019 Q3
Revenue	$550.7M	$500.7M	$494.6M
YoY Change	9.99%	15.26%	18.52%
Cost Of Revenue	$306.7M	$295.6M	$288.7M
YoY Change	3.76%	12.7%	15.62%
Gross Profit	$244.0M	$205.1M	$205.9M
YoY Change	18.97%	19.17%	22.85%
Gross Profit Margin	44.31%	40.96%	41.63%
Selling, General & Admin	$175.6M	$156.1M	$154.7M
YoY Change	12.49%	17.99%	24.26%
% of Gross Profit	71.97%	76.11%	75.13%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$8.800M	$6.000M	$4.300M
YoY Change	46.67%	76.47%	34.38%
% of Gross Profit	3.61%	2.93%	2.09%
Operating Expenses	$184.5M	$162.0M	$159.1M
YoY Change	13.89%	19.38%	24.59%
Operating Profit	$59.50M	$43.10M	$46.80M
YoY Change	38.05%	18.41%	17.29%
Interest Expense	-$800.0K	-$1.800M	$3.778M
YoY Change	-55.56%	500.0%	89.75%
% of Operating Profit	-1.34%	-4.18%	8.07%
Other Income/Expense, Net	$600.0K	-$400.0K	-$2.600M
YoY Change	-250.0%	-126.67%	-275.08%
Pretax Income	$62.00M	$39.40M	$44.24M
YoY Change	57.36%	7.65%	6.94%
Income Tax	$16.50M	$11.40M	$9.919M
% Of Pretax Income	26.61%	28.93%	22.42%
Net Earnings	$45.10M	$27.70M	$34.10M
YoY Change	62.82%	0.73%	8.6%
Net Earnings / Revenue	8.19%	5.53%	6.89%
Basic Earnings Per Share	$1.38	$0.86	$1.06
Diluted Earnings Per Share	$1.36	$0.83	$1.03
COMMON SHARES
Basic Shares Outstanding	32.81M shares	32.26M shares	32.21M shares
Diluted Shares Outstanding			33.00M shares

Balance Sheet

Concept	2020 Q4	2019 Q4	2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$81.80M	$30.30M	$20.80M
YoY Change	169.97%	50.0%	48.57%
Cash & Equivalents	$81.80M	$30.30M	$20.76M
Short-Term Investments
Other Short-Term Assets	$13.30M	$8.200M	$13.46M
YoY Change	62.2%	12.33%	12.63%
Inventory
Prepaid Expenses	$10.22M	$8.243M	$10.60M
Receivables	$255.1M	$237.6M	$254.7M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$362.0M	$350.6M	$299.5M
YoY Change	3.26%	56.41%	28.73%
LONG-TERM ASSETS
Property, Plant & Equipment	$23.70M	$28.10M	$29.97M
YoY Change	-15.66%	-4.42%	-0.81%
Goodwill	$932.7M	$658.5M	$660.5M
YoY Change	41.64%	99.85%	103.76%
Intangibles	$74.20M	$64.70M	$66.47M
YoY Change	14.68%	46.71%	50.01%
Long-Term Investments
YoY Change
Other Assets	$33.20M	$54.60M	$54.26M
YoY Change	-39.19%	0.92%	1.6%
Total Long-Term Assets	$1.205B	$912.2M	$912.9M
YoY Change	32.12%	85.03%	85.08%
TOTAL ASSETS
Total Short-Term Assets	$362.0M	$350.6M	$299.5M
Total Long-Term Assets	$1.205B	$912.2M	$912.9M
Total Assets	$1.567B	$1.263B	$1.212B
YoY Change	24.11%	76.09%	67.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$42.67M	$31.26M	$35.90M
YoY Change	36.52%	9.56%	46.42%
Accrued Expenses	$166.2M	$137.1M	$127.1M
YoY Change	21.23%	37.79%	25.63%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$10.50M	$9.900M	$9.000M
YoY Change	6.06%	518.75%	650.0%
Total Short-Term Liabilities	$456.3M	$326.9M	$314.7M
YoY Change	39.58%	46.96%	43.49%
LONG-TERM LIABILITIES
Long-Term Debt	$204.5M	$232.3M	$231.6M
YoY Change	-11.97%	3905.17%	321.86%
Other Long-Term Liabilities	$33.60M	$5.900M	$6.002M
YoY Change	469.49%	-4.84%	-4.01%
Total Long-Term Liabilities	$238.1M	$238.2M	$237.6M
YoY Change	-0.04%	1885.0%	288.54%
TOTAL LIABILITIES
Total Short-Term Liabilities	$456.3M	$326.9M	$314.7M
Total Long-Term Liabilities	$238.1M	$238.2M	$237.6M
Total Liabilities	$756.5M	$621.2M	$608.9M
YoY Change	21.77%	164.93%	117.16%
SHAREHOLDERS EQUITY
Retained Earnings	$430.0M	$246.4M	$218.7M
YoY Change	74.52%	106.09%	137.52%
Common Stock	$698.3M	$645.3M	$634.9M
YoY Change	8.22%	6.89%	7.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$319.1M	$251.2M	$251.1M
YoY Change	27.01%	3.95%	4.38%
Treasury Stock Shares	4.656M shares	4.354M shares	4.353M shares
Shareholders Equity	$809.2M	$640.5M	$602.6M
YoY Change
Total Liabilities & Shareholders Equity	$1.567B	$1.263B	$1.212B
YoY Change	24.11%	76.09%	67.02%

Cashflow Statement

Concept	2020 Q4	2019 Q4	2019 Q3
OPERATING ACTIVITIES
Net Income	$45.10M	$27.70M	$34.10M
YoY Change	62.82%	0.73%	8.6%
Depreciation, Depletion And Amortization	$8.800M	$6.000M	$4.300M
YoY Change	46.67%	76.47%	34.38%
Cash From Operating Activities	$66.00M	$75.20M	$47.50M
YoY Change	-12.23%	17.5%	-30.66%
INVESTING ACTIVITIES
Capital Expenditures	-$2.300M	-$1.600M	-$3.600M
YoY Change	43.75%	77.78%	-12.2%
Acquisitions
YoY Change
Other Investing Activities	$700.0K	$100.0K	$100.0K
YoY Change	600.0%	-101.15%	-103.03%
Cash From Investing Activities	-$1.600M	-$1.300M	-$3.600M
YoY Change	23.08%	-86.46%	-51.35%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-96.50M	1.900M	-37.00M
YoY Change	-5178.95%	-103.94%	-49.32%
NET CHANGE
Cash From Operating Activities	66.00M	75.20M	47.50M
Cash From Investing Activities	-1.600M	-1.300M	-3.600M
Cash From Financing Activities	-96.50M	1.900M	-37.00M
Net Change In Cash	-32.10M	75.80M	6.900M
YoY Change	-142.35%	1122.58%	-157.98%
FREE CASH FLOW
Cash From Operating Activities	$66.00M	$75.20M	$47.50M
Capital Expenditures	-$2.300M	-$1.600M	-$3.600M
Free Cash Flow	$68.30M	$76.80M	$51.10M
YoY Change	-11.07%	18.34%	-29.61%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0000896262
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	83357000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	38859000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	38859000	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	1778161000	USD
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	1507430000	USD
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	0-24260
CY2020	dei	Entity Registrant Name EntityRegistrantName	AMEDISYS, INC.
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	11-3131700
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	3854 American Way, Suite A,
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Baton Rouge,
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	LA
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	70816
CY2020	dei	City Area Code CityAreaCode	225
CY2020	dei	Local Phone Number LocalPhoneNumber	292-2031
CY2020	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2020	dei	Trading Symbol TradingSymbol	AMED
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	false
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	5500000000	USD
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	32848547	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	81808000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30294000	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	1549000	USD
CY2019Q4	us-gaap	Restricted Cash RestrictedCash	66196000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	255145000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	237596000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	10217000	USD
CY2019Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8243000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	13265000	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	8225000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	361984000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	350554000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	95024000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	96137000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	23719000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28113000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	93440000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	84791000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	932685000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	658500000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	22973000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	7044000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	74183000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	64748000	USD
CY2020Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	47987000	USD
CY2019Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	21427000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	33200000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	54612000	USD
CY2020Q4	us-gaap	Assets Assets	1567198000	USD
CY2019Q4	us-gaap	Assets Assets	1262745000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	42674000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	31259000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	146929000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	120877000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	166192000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	137111000	USD
CY2020Q4	amed	Provider Relief Fund Advance ProviderReliefFundAdvance	60000000	USD
CY2019Q4	amed	Provider Relief Fund Advance ProviderReliefFundAdvance	0	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	10496000	USD
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	9927000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	30046000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	27769000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	456337000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	326943000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	204511000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	232256000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	61987000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	56128000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	33622000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5905000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	756457000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	621232000	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2019Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37470212	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36638021	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32814278	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32284051	shares
CY2020Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	38000	USD
CY2019Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	37000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	698287000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	645256000	USD
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	4655934	shares
CY2019	us-gaap	Health Care Organization Revenue Net Of Patient Service Revenue Provisions HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions	1955633000	USD
CY2019Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	4353970	shares
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	319092000	USD
CY2019Q4	us-gaap	Treasury Stock Value TreasuryStockValue	251241000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	15000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	429991000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	246383000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	809224000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	640450000	USD
CY2020Q4	us-gaap	Minority Interest MinorityInterest	1517000	USD
CY2019Q4	us-gaap	Minority Interest MinorityInterest	1063000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	810741000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	641513000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1567198000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1262745000	USD
CY2020	us-gaap	Health Care Organization Revenue Net Of Patient Service Revenue Provisions HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions	2071519000	USD
CY2018	us-gaap	Health Care Organization Revenue Net Of Patient Service Revenue Provisions HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions	1662578000	USD
CY2020	us-gaap	Other Operating Income OtherOperatingIncome	34372000	USD
CY2019	us-gaap	Other Operating Income OtherOperatingIncome	0	USD
CY2018	us-gaap	Other Operating Income OtherOperatingIncome	0	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1185369000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1150337000	USD
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	992863000	USD
CY2020	us-gaap	Labor And Related Expense LaborAndRelatedExpense	449448000	USD
CY2019	us-gaap	Labor And Related Expense LaborAndRelatedExpense	394452000	USD
CY2018	us-gaap	Labor And Related Expense LaborAndRelatedExpense	316522000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	26730000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	25040000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	17887000	USD
CY2020	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	192122000	USD
CY2019	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	188434000	USD
CY2018	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	166897000	USD
CY2020	amed	Depreciation And Amortization For Continuing Operations DepreciationAndAmortizationForContinuingOperations	28802000	USD
CY2019	amed	Depreciation And Amortization For Continuing Operations DepreciationAndAmortizationForContinuingOperations	18428000	USD
CY2018	amed	Depreciation And Amortization For Continuing Operations DepreciationAndAmortizationForContinuingOperations	13261000	USD
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	4152000	USD
CY2019	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1470000	USD
CY2018	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	1886623000	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	1778161000	USD
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	1507430000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	219268000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	177472000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	155148000	USD
CY2020	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	292000	USD
CY2019	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	78000	USD
CY2018	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	278000	USD
CY2020	us-gaap	Interest Expense InterestExpense	11038000	USD
CY2019	us-gaap	Interest Expense InterestExpense	14515000	USD
CY2018	us-gaap	Interest Expense InterestExpense	7370000	USD
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	3966000	USD
CY2019	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	5338000	USD
CY2018	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	7692000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1669000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2037000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3240000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8449000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7062000	USD
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3840000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	210819000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	170410000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	158988000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	25635000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	42503000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	38859000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	185184000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	127907000	USD
CY2018	us-gaap	Profit Loss ProfitLoss	120129000	USD
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	1576000	USD
CY2019	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	1074000	USD
CY2018	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	783000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	183608000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	126833000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	119346000	USD
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	5.64
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.95
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.64
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32559000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32142000	shares
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32791000	shares
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	5.52
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.84
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.55
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33268000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32990000	shares
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33609000	shares
CY2020	us-gaap	Profit Loss ProfitLoss	185184000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	127907000	USD
CY2018	us-gaap	Profit Loss ProfitLoss	120129000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	185184000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	127907000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	120129000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	1576000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	1074000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	783000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	183608000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	126833000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	119346000	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	516426000	USD
CY2018	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2429000	USD
CY2018	amed	Stock Issued During Period Value Four Zero One K Employer Match StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch	9232000	USD
CY2018	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5953000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17887000	USD
CY2018	amed	Surrendered Shares SurrenderedShares	-6570000	USD
CY2018	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	181402000	USD
CY2018	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	1090000	USD
CY2018	amed	Equity Impactof Repurchaseof Noncontrolling Interest EquityImpactofRepurchaseofNoncontrollingInterest	-361000	USD
CY2018	us-gaap	Profit Loss ProfitLoss	120129000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	482633000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	25040000	USD
CY2019	amed	Surrendered Shares SurrenderedShares	-9556000	USD
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3187000	USD
CY2019	amed	Stock Issued During Period Value Four Zero One K Employer Match StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch	9753000	USD
CY2019	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3611000	USD
CY2019	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	1062000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	127907000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	641513000	USD
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3562000	USD
CY2020	amed	Stock Issued During Period Value Four Zero One K Employer Match StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch	3057000	USD
CY2020	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6325000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	26730000	USD
CY2020	amed	Surrendered Shares SurrenderedShares	-54493000	USD
CY2020	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	1122000	USD
CY2020	amed	Equity Impact Of Write Off Of Other Comprehensive Income EquityImpactOfWriteOffOfOtherComprehensiveIncome	15000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	185184000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	810741000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	185184000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	127907000	USD
CY2018	us-gaap	Profit Loss ProfitLoss	120129000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	28802000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	18428000	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13261000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	26730000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	25040000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	17887000	USD
CY2020	us-gaap	Pension Expense PensionExpense	0	USD
CY2019	us-gaap	Pension Expense PensionExpense	10509000	USD
CY2018	us-gaap	Pension Expense PensionExpense	8976000	USD
CY2020	amed	Amortization And Impairment Of Operating Lease Right Of Use Asset AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset	39140000	USD
CY2019	amed	Amortization And Impairment Of Operating Lease Right Of Use Asset AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset	35905000	USD
CY2018	amed	Amortization And Impairment Of Operating Lease Right Of Use Asset AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset	0	USD
CY2019	amed	Write Off Of Other Comprehensive Income WriteOffOfOtherComprehensiveIncome	0	USD
CY2018	amed	Write Off Of Other Comprehensive Income WriteOffOfOtherComprehensiveIncome	0	USD
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	30000	USD
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-141000	USD
CY2018	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-714000	USD
CY2020	us-gaap	Loss On Sale Of Investments LossOnSaleOfInvestments	2980000	USD
CY2019	us-gaap	Loss On Sale Of Investments LossOnSaleOfInvestments	0	USD
CY2018	us-gaap	Loss On Sale Of Investments LossOnSaleOfInvestments	0	USD
CY2020	amed	Write Off Of Other Comprehensive Income WriteOffOfOtherComprehensiveIncome	15000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-26560000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	13466000	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	20271000	USD
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	3966000	USD
CY2019	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	5338000	USD
CY2018	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	7692000	USD
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	869000	USD
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	873000	USD
CY2018	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	797000	USD
CY2020	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	5444000	USD
CY2019	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	4955000	USD
CY2018	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	6158000	USD
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	4152000	USD
CY2019	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1470000	USD
CY2018	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2114000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	24146000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-12224000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7181000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2682000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-8679000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-31000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-832000	USD
CY2018	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-2947000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1941000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-11329000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-329000	USD
CY2018	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	2443000	USD
CY2020	amed	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-34695000	USD
CY2019	amed	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-32295000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3165000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	39839000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	42096000	USD
CY2018	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	13524000	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	27717000	USD
CY2018	amed	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	USD
CY2020	amed	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-3544000	USD
CY2019	amed	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-3503000	USD
CY2018	amed	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	0	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	288952000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	202000000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	223483000	USD
CY2020	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	101000	USD
CY2019	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	448000	USD
CY2018	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	715000	USD
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	80000	USD
CY2019	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	162000	USD
CY2018	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	54000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5332000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7888000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6558000	USD
CY2020	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	875000	USD
CY2019	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	210000	USD
CY2018	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	7144000	USD
CY2020	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	17876000	USD
CY2019	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	0	USD
CY2018	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	0	USD
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	298958000	USD
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	345460000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5953000	USD
CY2020	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	3562000	USD
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	9556000	USD
CY2018	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	9260000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-287108000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-352948000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-22193000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6325000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3611000	USD
CY2019	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	3187000	USD
CY2018	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2429000	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	54493000	USD
CY2018	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	6570000	USD
CY2020	amed	Cash Distribution To Noncontrolling Interest CashDistributionToNoncontrollingInterest	1122000	USD
CY2019	amed	Cash Distribution To Noncontrolling Interest CashDistributionToNoncontrollingInterest	1062000	USD
CY2018	amed	Cash Distribution To Noncontrolling Interest CashDistributionToNoncontrollingInterest	1090000	USD
CY2020	amed	Proceeds From Borrowings Under Term Loan ProceedsFromBorrowingsUnderTermLoan	0	USD
CY2019	amed	Proceeds From Borrowings Under Term Loan ProceedsFromBorrowingsUnderTermLoan	175000000	USD
CY2018	amed	Proceeds From Borrowings Under Term Loan ProceedsFromBorrowingsUnderTermLoan	0	USD
CY2020	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	684200000	USD
CY2019	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	262500000	USD
CY2018	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	138000000	USD
CY2020	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	703200000	USD
CY2019	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	200000000	USD
CY2018	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	130500000	USD
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	10249000	USD
CY2019	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	5624000	USD
CY2018	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	91450000	USD
CY2020	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2019	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	847000	USD
CY2018	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	2433000	USD
CY2020	amed	Funds Received From Provider Relief Fund Advance FundsReceivedFromProviderReliefFundAdvance	60000000	USD
CY2019	amed	Funds Received From Provider Relief Fund Advance FundsReceivedFromProviderReliefFundAdvance	0	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	83357000	USD
CY2018	amed	Funds Received From Provider Relief Fund Advance FundsReceivedFromProviderReliefFundAdvance	0	USD
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2019	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2018	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	181402000	USD
CY2020	amed	Payments For Repurchase Of Noncontrolling Interest PaymentsForRepurchaseOfNoncontrollingInterest	0	USD
CY2019	amed	Payments For Repurchase Of Noncontrolling Interest PaymentsForRepurchaseOfNoncontrollingInterest	0	USD
CY2018	amed	Payments For Repurchase Of Noncontrolling Interest PaymentsForRepurchaseOfNoncontrollingInterest	361000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-14977000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	227209000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-267424000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-13133000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	76261000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-66134000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	96490000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20229000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	86363000	USD
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	29522000	USD
CY2018	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	14278000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	96490000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20229000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	6207000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	9628000	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	3522000	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	50721000	USD
CY2020	us-gaap	Notes Assumed1 NotesAssumed1	0	USD
CY2019	us-gaap	Notes Assumed1 NotesAssumed1	0	USD
CY2018	us-gaap	Notes Assumed1 NotesAssumed1	418000	USD
CY2020Q4	us-gaap	Number Of States In Which Entity Operates NumberOfStatesInWhichEntityOperates	39	state
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting and reporting policies conform with U.S. GAAP. In preparing the consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.</span></div>
CY2018Q4	amed	Noncontrolling Interest Repurchased NoncontrollingInterestRepurchased	0.30
CY2020Q4	amed	Minimum Percent Ownership For Controlling Interest Percent MinimumPercentOwnershipForControllingInterestPercent	0.50
CY2020Q4	amed	Maximum Percent Ownership For Equity Method Percent MaximumPercentOwnershipForEquityMethodPercent	0.50
CY2020Q4	us-gaap	Equity Method Investment Aggregate Cost EquityMethodInvestmentAggregateCost	14200000	USD
CY2019Q4	us-gaap	Equity Method Investment Aggregate Cost EquityMethodInvestmentAggregateCost	35700000	USD
CY2020	amed	Historical Collection Rate From Medicare HistoricalCollectionRateFromMedicare	0.99
CY2020	amed	Hospice Medicare Revenue Rate Accounted For Routine Care HospiceMedicareRevenueRateAccountedForRoutineCare	0.97
CY2020	amed	Revenuebypayorclassasapercentageoftotalnetservicerevenue Revenuebypayorclassasapercentageoftotalnetservicerevenue	1
CY2019	amed	Revenuebypayorclassasapercentageoftotalnetservicerevenue Revenuebypayorclassasapercentageoftotalnetservicerevenue	1
CY2018	amed	Revenuebypayorclassasapercentageoftotalnetservicerevenue Revenuebypayorclassasapercentageoftotalnetservicerevenue	1
CY2020	amed	Net Service Revenue Period Of Care Payment Rate Duration NetServiceRevenuePeriodOfCarePaymentRateDuration	P30D
CY2020	amed	Net Service Revenue Episode Payment Rate Duration NetServiceRevenueEpisodePaymentRateDuration	P60D
CY2020	amed	Net Service Revenue Period Of Care Payment Rate Duration NetServiceRevenuePeriodOfCarePaymentRateDuration	P30D
CY2020	amed	Percentage Of Total Reimbursement Of Outlier Payment PercentageOfTotalReimbursementOfOutlierPayment	0.10
CY2020	amed	Net Service Revenue Period Of Care Payment Rate Duration NetServiceRevenuePeriodOfCarePaymentRateDuration	P30D
CY2020	amed	Rate Of Request For Anticipated Payment Submitted For Initial Period Of Care RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare	0.20
CY2018	amed	Hospice Medicare Revenue Rate Accounted For Routine Care HospiceMedicareRevenueRateAccountedForRoutineCare	0.97
CY2019	amed	Hospice Medicare Revenue Rate Accounted For Routine Care HospiceMedicareRevenueRateAccountedForRoutineCare	0.97
CY2020Q4	amed	Cash Balance Associated With Provider Relief Fund CashBalanceAssociatedWithProviderReliefFund	77000000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	81800000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30300000	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	1500000	USD
CY2019Q4	us-gaap	Restricted Cash RestrictedCash	66200000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	96500000	USD
CY2020	amed	Percentage Of Patient Receivables Outstanding PercentageOfPatientReceivablesOutstanding	0.10
CY2020	amed	Portion Of Patient Accounts Receivable Derived From Medicare PortionOfPatientAccountsReceivableDerivedFromMedicare	0.64
CY2020	us-gaap	Depreciation Depreciation	12100000	USD
CY2019	us-gaap	Depreciation Depreciation	11600000	USD
CY2019	amed	Portion Of Patient Accounts Receivable Derived From Medicare PortionOfPatientAccountsReceivableDerivedFromMedicare	0.58
CY2020	amed	Historical Collection Rate From Medicare HistoricalCollectionRateFromMedicare	0.99
CY2020	amed	Rate Of Request For Anticipated Payment Submitted For Initial Period Of Care RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare	0.20
CY2020	amed	Maximum Days To Submit Final Bill From Start Of Period Of Care MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare	90	day
CY2020	amed	Maximum Days To Submit Final Bill From Date Request For Anticipated Payment Was Paid MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid	60	day
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	118700000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	124200000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	95000000.0	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	96100000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	23700000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28100000	USD
CY2019	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	800000	USD
CY2018	us-gaap	Depreciation Depreciation	10800000	USD
CY2020Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	2700000	USD
CY2019Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	3500000	USD
CY2020Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	2700000	USD
CY2020	amed	Unamortized Debt Issuance Cost Amortization Period UnamortizedDebtIssuanceCostAmortizationPeriod	P3Y1M6D
CY2020Q4	amed	Debt Instrument Carrying Amount Excluding Finance Leases DebtInstrumentCarryingAmountExcludingFinanceLeases	215100000	USD
CY2020Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	48000000.0	USD
CY2019Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	21400000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	26700000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	25000000.0	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	17900000	USD
CY2020	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	4700000	USD
CY2019	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	4600000	USD
CY2018	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	4300000	USD
CY2019	amed	Non Vested Stock And Stock Units NonVestedStockAndStockUnits	303000	shares
CY2018	amed	Non Vested Stock And Stock Units NonVestedStockAndStockUnits	316000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32559000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32142000	shares
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32791000	shares
CY2020	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	420000	shares
CY2019	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	545000	shares
CY2018	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	502000	shares
CY2020	amed	Non Vested Stock And Stock Units NonVestedStockAndStockUnits	289000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33268000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32990000	shares
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33609000	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	25000	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	117000	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	50000	shares
CY2020	us-gaap	Advertising Expense AdvertisingExpense	8000000.0	USD
CY2019	us-gaap	Advertising Expense AdvertisingExpense	8500000	USD
CY2018	us-gaap	Advertising Expense AdvertisingExpense	7000000.0	USD
CY2020Q1	amed	Funding For Healthcare Providers Including Hospitals FundingForHealthcareProvidersIncludingHospitals	175000000000	USD
CY2020Q1	amed	Funding Immediately Distributed To Healthcare Providers Based On Their2019 Medicare Fee For Service Reimbursements FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements	30000000000	USD
CY2020Q2	amed	Funding Received From Cares Act FundingReceivedFromCARESAct	100000000	USD
CY2020Q1	amed	Funding Immediately Distributed To Healthcare Providers Based On Their2019 Medicare Fee For Service Reimbursements FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements	30000000000	USD
CY2020Q4	amed	Provider Relief Fund Advance ProviderReliefFundAdvance	60000000	USD
CY2020	amed	Estimated Future Covid19 Related Expenses EstimatedFutureCOVID19RelatedExpenses	12000000	USD
CY2020	amed	Cares Act Provider Relief Funds Utilized CARESActProviderReliefFundsUtilized	33300000	USD
CY2020Q4	amed	Estimated Cares Act Provider Relief Funds Expected To Be Utilized EstimatedCARESActProviderReliefFundsExpectedToBeUtilized	11600000	USD
CY2020Q4	amed	Estimated Cares Act Provider Relief Fund Amounts To Be Repaid EstimatedCARESActProviderReliefFundAmountsToBeRepaid	60000000.0	USD
CY2020Q4	amed	Cares Act Provider Relief Funds Received By Unconsolidated Joint Ventures CARESActProviderReliefFundsReceivedByUnconsolidatedJointVentures	1900000	USD
CY2020Q4	amed	Total Cares Act Provider Relief Funds Received TotalCARESActProviderReliefFundsReceived	106800000	USD
CY2020Q2	amed	Additional Funding Distributed To Healthcare Providers AdditionalFundingDistributedToHealthcareProviders	18000000000	USD
CY2020Q4	amed	Additional Funding Distributed To Healthcare Providers AdditionalFundingDistributedToHealthcareProviders	20000000000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	44100000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	329500000	USD
CY2019	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	329000000.0	USD
CY2019Q4	us-gaap	Goodwill Goodwill	658500000	USD
CY2020	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	274200000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	932700000	USD
CY2020Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	733700000	USD
CY2019	amed	Other Intangible Assets Additions OtherIntangibleAssetsAdditions	28900000	USD
CY2019	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	1500000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6800000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	64700000	USD
CY2020	amed	Other Intangible Assets Additions OtherIntangibleAssetsAdditions	30300000	USD
CY2020	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	4200000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	16600000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	74200000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	10600000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2700000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	0	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	0	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	0	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	13300000	USD
CY2020Q4	amed	Payroll Tax Escrow PayrollTaxEscrow	6300000	USD
CY2019Q4	amed	Payroll Tax Escrow PayrollTaxEscrow	1500000	USD
CY2020Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	200000	USD
CY2019Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	2000000.0	USD
CY2020Q4	us-gaap	Due From Joint Ventures Current DueFromJointVenturesCurrent	2300000	USD
CY2019Q4	us-gaap	Due From Joint Ventures Current DueFromJointVenturesCurrent	2000000.0	USD
CY2020Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	4500000	USD
CY2019Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	2700000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	13300000	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	8200000	USD
CY2020Q4	amed	Workers Compensation Deposits WorkersCompensationDeposits	300000	USD
CY2019Q4	amed	Workers Compensation Deposits WorkersCompensationDeposits	200000	USD
CY2020Q4	amed	Health Insurance Deposits HealthInsuranceDeposits	500000	USD
CY2019Q4	amed	Health Insurance Deposits HealthInsuranceDeposits	500000	USD
CY2020Q4	amed	Other Miscellaneous Deposits OtherMiscellaneousDeposits	1200000	USD
CY2019Q4	amed	Other Miscellaneous Deposits OtherMiscellaneousDeposits	1000000.0	USD
CY2020Q4	us-gaap	Loss Contingency Receivable Noncurrent LossContingencyReceivableNoncurrent	13600000	USD
CY2019Q4	us-gaap	Loss Contingency Receivable Noncurrent LossContingencyReceivableNoncurrent	13600000	USD
CY2020Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	14200000	USD
CY2019Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	35700000	USD
CY2020Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	3400000	USD
CY2019Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	3600000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	33200000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	54600000	USD
CY2020Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	15100000	USD
CY2019Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	15800000	USD
CY2020Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	35800000	USD
CY2019Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	33400000	USD
CY2020Q4	amed	Provision For Liability On Regulatory Audit ProvisionForLiabilityOnRegulatoryAudit	17400000	USD
CY2019Q4	amed	Provision For Liability On Regulatory Audit ProvisionForLiabilityOnRegulatoryAudit	17400000	USD
CY2020Q4	amed	Legal And Other Settlements LegalAndOtherSettlements	24400000	USD
CY2019Q4	amed	Legal And Other Settlements LegalAndOtherSettlements	19000000.0	USD
CY2020Q4	amed	Uncertain Tax Benefits In Long Term Obligations UncertainTaxBenefitsInLongTermObligations	3300000	USD
CY2019Q4	amed	Uncertain Tax Benefits In Long Term Obligations UncertainTaxBenefitsInLongTermObligations	3100000	USD
CY2020Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0	USD
CY2019Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	500000	USD
CY2020Q4	amed	Charity Care CharityCare	3600000	USD
CY2019Q4	amed	Charity Care CharityCare	2700000	USD
CY2020Q4	amed	Estimated Medicare Cap Liability EstimatedMedicareCapLiability	9300000	USD
CY2019Q4	amed	Estimated Medicare Cap Liability EstimatedMedicareCapLiability	5700000	USD
CY2020Q4	amed	Hospice Accruals HospiceAccruals	29200000	USD
CY2019Q4	amed	Hospice Accruals HospiceAccruals	24400000	USD
CY2020Q4	amed	Patient Liability PatientLiability	8400000	USD
CY2019Q4	amed	Patient Liability PatientLiability	9400000	USD
CY2020Q4	amed	Deferred Operating Income Cares Act DeferredOperatingIncomeCARESAct	11600000	USD
CY2019Q4	amed	Deferred Operating Income Cares Act DeferredOperatingIncomeCARESAct	0	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	11400000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8800000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	166200000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	137100000	USD
CY2020Q4	amed	Deferred Compensation Plan Liability DeferredCompensationPlanLiability	1000000.0	USD
CY2019Q4	amed	Deferred Compensation Plan Liability DeferredCompensationPlanLiability	1000000.0	USD
CY2020Q4	amed	Non Current Social Security Taxes Deferred Under Cares Act NonCurrentSocialSecurityTaxesDeferredUnderCARESAct	27700000	USD
CY2019Q4	amed	Non Current Social Security Taxes Deferred Under Cares Act NonCurrentSocialSecurityTaxesDeferredUnderCARESAct	0	USD
CY2020Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	1600000	USD
CY2019Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	1800000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	33600000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5900000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P8Y
CY2020Q4	us-gaap	Lessee Finance Lease Term Of Contract1 LesseeFinanceLeaseTermOfContract1	P3Y
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	38600000	USD
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	35000000.0	USD
CY2020	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	500000	USD
CY2019	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	900000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	39100000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	35900000	USD
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	2000000.0	USD
CY2019	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1700000	USD
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	200000	USD
CY2019	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	200000	USD
CY2020	amed	Finance Lease Cost FinanceLeaseCost	2200000	USD
CY2019	amed	Finance Lease Cost FinanceLeaseCost	1900000	USD
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	3000000.0	USD
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	2600000	USD
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	USD
CY2019	us-gaap	Short Term Lease Cost ShortTermLeaseCost	200000	USD
CY2020	us-gaap	Lease Cost LeaseCost	44300000	USD
CY2019	us-gaap	Lease Cost LeaseCost	40600000	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	3300000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	38500000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	62000000.0	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	56100000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	93400000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	84800000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	30000000.0	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	27800000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	92000000.0	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	83900000	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	5900000	USD
CY2019Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	5200000	USD
CY2019Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1700000	USD
CY2020Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	2600000	USD
CY2019Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	1800000	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	2600000	USD
CY2019Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	3400000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1700000	USD
CY2019Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1700000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	900000	USD
CY2019Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	3400000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	38200000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	35800000	USD
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	2000000.0	USD
CY2019	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1700000	USD
CY2019	amed	Lessee Finance Lease Reduction To Rou Assets Resulting From Reductions To Lease Obligations LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations	0	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	116000000.0	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	1200000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	2900000	USD
CY2020	amed	Lessee Operating Lease Reductions To Rou Assets Resulting From Reductions To Lease Obligations LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations	-1100000	USD
CY2019	amed	Lessee Operating Lease Reductions To Rou Assets Resulting From Reductions To Lease Obligations LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations	-1700000	USD
CY2020	amed	Lessee Finance Lease Reduction To Rou Assets Resulting From Reductions To Lease Obligations LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations	0	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y8M12D
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y10M24D
CY2020Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y8M12D
CY2019Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y1M6D
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.031
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.039
CY2020Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.053
CY2020Q4	amed	Consolidated Interest Coverage Ratio ConsolidatedInterestCoverageRatio	25.6
CY2019Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.053
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	32200000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	1800000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	25300000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	700000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	17600000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	200000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	11700000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	0	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	6200000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	0	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	4600000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	0	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	97600000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	2700000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5600000	USD
CY2020Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	100000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	92000000.0	USD
CY2020Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	2600000	USD
CY2020Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	217700000	USD
CY2019Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	245700000	USD
CY2020Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	2700000	USD
CY2019Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	3500000	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	215000000.0	USD
CY2019Q4	us-gaap	Long Term Debt LongTermDebt	242200000	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	10500000	USD
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	9900000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	204500000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	232300000	USD
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	10500000	USD
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	9400000	USD
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	12300000	USD
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	185500000	USD
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	0	USD
CY2020Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	217700000	USD
CY2020Q4	amed	Total Leverage Ratio TotalLeverageRatio	0.6
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	29000000.0	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	41600000	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	24200000	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	16400000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	10600000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	4800000	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2100000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	52200000	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	18500000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-22500000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	9500000	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	14500000	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-4100000	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	4000000.0	USD
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	5800000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-26600000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other Loss Carryforwards DeferredTaxAssetsOtherLossCarryforwards	3700000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	2900000	USD
CY2019Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	2000000.0	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	13500000	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	20300000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	25600000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	42500000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	25600000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	42500000	USD
CY2020	amed	Income Tax Effects Allocated To Interest Expense IncomeTaxEffectsAllocatedToInterestExpense	200000	USD
CY2019	amed	Income Tax Effects Allocated To Interest Expense IncomeTaxEffectsAllocatedToInterestExpense	300000	USD
CY2018	amed	Income Tax Effects Allocated To Interest Expense IncomeTaxEffectsAllocatedToInterestExpense	100000	USD
CY2020	amed	Income Tax Effects Allocated To Goodwill IncomeTaxEffectsAllocatedToGoodwill	0	USD
CY2019	amed	Income Tax Effects Allocated To Goodwill IncomeTaxEffectsAllocatedToGoodwill	900000	USD
CY2018	amed	Income Tax Effects Allocated To Goodwill IncomeTaxEffectsAllocatedToGoodwill	0	USD
CY2020	us-gaap	Income Tax Expense Benefit Intraperiod Tax Allocation IncomeTaxExpenseBenefitIntraperiodTaxAllocation	25800000	USD
CY2019	us-gaap	Income Tax Expense Benefit Intraperiod Tax Allocation IncomeTaxExpenseBenefitIntraperiodTaxAllocation	43700000	USD
CY2018	us-gaap	Income Tax Expense Benefit Intraperiod Tax Allocation IncomeTaxExpenseBenefitIntraperiodTaxAllocation	38900000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.024
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.048
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.048
CY2020	amed	Effective Income Tax Rate Reconciliation Excess Tax Benefit Sharebased Compensation Percent EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent	0.127
CY2019	amed	Effective Income Tax Rate Reconciliation Excess Tax Benefit Sharebased Compensation Percent EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent	0.022
CY2018	amed	Effective Income Tax Rate Reconciliation Excess Tax Benefit Sharebased Compensation Percent EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent	0.018
CY2020	amed	Effective Income Tax Rate Reconciliation Non Deductible Executive Compensation Percent EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent	0.021
CY2019	amed	Effective Income Tax Rate Reconciliation Non Deductible Executive Compensation Percent EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent	0.016
CY2018	amed	Effective Income Tax Rate Reconciliation Non Deductible Executive Compensation Percent EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent	0.004
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.006
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.003
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.122
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.249
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.244
CY2020Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	200000	USD
CY2019Q4	amed	Deferred Tax Assets Legal And Compliance Matters DeferredTaxAssetsLegalAndComplianceMatters	4800000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Other DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther	15900000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Other DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther	15100000	USD
CY2020Q4	amed	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Workers Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation	9600000	USD
CY2019Q4	amed	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Workers Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation	9000000.0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5100000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	7900000	USD
CY2020Q4	amed	Deferred Tax Assets Legal And Compliance Matters DeferredTaxAssetsLegalAndComplianceMatters	7000000.0	USD
CY2020Q4	amed	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	25200000	USD
CY2019Q4	amed	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	23100000	USD
CY2020Q4	amed	Deferred Tax Assets Provider Relief Fund Advance DeferredTaxAssetsProviderReliefFundAdvance	15600000	USD
CY2019Q4	amed	Deferred Tax Assets Provider Relief Fund Advance DeferredTaxAssetsProviderReliefFundAdvance	0	USD
CY2020Q4	amed	Deferred Tax Asset Deferred Social Security Taxes DeferredTaxAssetDeferredSocialSecurityTaxes	14300000	USD
CY2019Q4	amed	Deferred Tax Asset Deferred Social Security Taxes DeferredTaxAssetDeferredSocialSecurityTaxes	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other Loss Carryforwards DeferredTaxAssetsOtherLossCarryforwards	2400000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	98500000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	66800000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	3100000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	600000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	500000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	98600000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	67200000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	100000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	400000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	3800000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	4300000	USD
CY2020Q4	amed	Deferred Tax Liabilities Amortization Of Intangible Assets DeferredTaxLiabilitiesAmortizationOfIntangibleAssets	11800000	USD
CY2019Q4	amed	Deferred Tax Liabilities Amortization Of Intangible Assets DeferredTaxLiabilitiesAmortizationOfIntangibleAssets	300000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Tax Deferred Income DeferredTaxLiabilitiesTaxDeferredIncome	9000000.0	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Tax Deferred Income DeferredTaxLiabilitiesTaxDeferredIncome	13500000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Investment In Noncontrolled Affiliates DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates	0	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Investment In Noncontrolled Affiliates DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates	3300000	USD
CY2020Q4	amed	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	24900000	USD
CY2019Q4	amed	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	22800000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	1000000.0	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	1200000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	50500000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	45400000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	48000000.0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	21400000	USD
CY2020Q2	amed	Funding Received From Cares Act FundingReceivedFromCARESAct	100000000	USD
CY2020Q4	amed	Provider Relief Fund Advance ProviderReliefFundAdvance	60000000	USD
CY2020Q4	amed	Provider Relief Fund Advance ProviderReliefFundAdvance	60000000	USD
CY2020Q4	amed	Cares Act Deferral Of Employer Share Social Security Tax CARESActDeferralOfEmployerShareSocialSecurityTax	55400000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	100000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	400000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	300000	USD
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	300000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2700000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2700000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2700000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2018	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2700000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2700000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2700000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2700000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2700000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	200000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	300000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	100000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	600000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	400000	USD
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37470212	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32814278	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020	amed	Percentageofownershipinsubsidiaries Percentageofownershipinsubsidiaries	0.50
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	2500000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2000000.0	shares
CY2020	amed	Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries	0.10
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Purchase Date ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate	0.85
CY2020Q4	amed	Common Stock Shares Authorized For Issuance To Employee Stock Purchase Plan CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan	1328627	shares
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	3122983	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased	15.92
CY2019Q1	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	7181	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased	104.77
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased	168.76
CY2019Q2	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	8230	shares
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased	103.20
CY2019Q3	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	7216	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased	111.36
CY2019Q4	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	6063	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased	141.88
CY2020Q1	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	5295	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased	156.01
CY2020Q2	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	5414	shares
CY2020Q3	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	4789	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased	200.97
CY2020Q4	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	4202	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased	249.33
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	3171373	shares
CY2020	us-gaap	Employee Stock Ownership Plan Esop Compensation Expense EmployeeStockOwnershipPlanESOPCompensationExpense	600000	USD
CY2019	us-gaap	Employee Stock Ownership Plan Esop Compensation Expense EmployeeStockOwnershipPlanESOPCompensationExpense	600000	USD
CY2018	us-gaap	Employee Stock Ownership Plan Esop Compensation Expense EmployeeStockOwnershipPlanESOPCompensationExpense	500000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	875974	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	49.62
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y3M3D
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	43249	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	209.41
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	622829	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	31.60
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	18353	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	103.89
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	278041	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	111.27
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M4D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	18154	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	89429	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	76.40
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y9M
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	305750	shares
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	41.66
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	43249	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	86.72
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	142233	shares
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	34.84
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	47.66
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	188612	shares
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	56.55
CY2020	amed	Health Insurance HealthInsurance	15100000	USD
CY2019	amed	Health Insurance HealthInsurance	15800000	USD
CY2020	amed	Wokers Compensation WokersCompensation	35800000	USD
CY2019	amed	Wokers Compensation WokersCompensation	33400000	USD
CY2020	amed	Professional Liability ProfessionalLiability	4900000	USD
CY2019	amed	Professional Liability ProfessionalLiability	5100000	USD
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	9000000.0	USD
CY2020	amed	Estimated Insurance Long Term Portion EstimatedInsuranceLongTermPortion	1200000	USD
CY2019	amed	Estimated Insurance Long Term Portion EstimatedInsuranceLongTermPortion	1300000	USD
CY2020	amed	Estimated Insurance Total EstimatedInsuranceTotal	55800000	USD
CY2019	amed	Estimated Insurance Total EstimatedInsuranceTotal	54300000	USD
CY2020	amed	Estimated Insurance Excluding Long Term Portion EstimatedInsuranceExcludingLongTermPortion	54600000	USD
CY2019	amed	Estimated Insurance Excluding Long Term Portion EstimatedInsuranceExcludingLongTermPortion	53000000.0	USD
CY2020	amed	Health Insurance Retention Limit HealthInsuranceRetentionLimit	1300000	USD
CY2020	amed	Workers Compensation Insurance Retention Limit WorkersCompensationInsuranceRetentionLimit	1000000.0	USD
CY2020	amed	Professional Liability Insurance Retention Limit ProfessionalLiabilityInsuranceRetentionLimit	300000	USD
CY2020	amed	Defined Contribution Plan Employer Matching Contribution DefinedContributionPlanEmployerMatchingContribution	0.44	USD
CY2020	amed	Defined Contribution Plan Employee Contribution For Employee Matching Program DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram	1.00	USD
CY2020	amed	Defind Contribution Plan Maximum Annual Match Per Employee Salary Percentage DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage	0.06
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	12900000	USD
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	10500000	USD
CY2020	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	segment
CY2020	us-gaap	Health Care Organization Revenue Net Of Patient Service Revenue Provisions HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions	2071500000	USD
CY2020	us-gaap	Other Operating Income OtherOperatingIncome	34400000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1185400000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	668200000	USD
CY2020	amed	Depreciation And Amortization For Continuing Operations DepreciationAndAmortizationForContinuingOperations	28800000	USD
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	4200000	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	1886600000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	219300000	USD
CY2019	us-gaap	Health Care Organization Revenue Net Of Patient Service Revenue Provisions HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions	1955600000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1150300000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	607900000	USD
CY2019	amed	Depreciation And Amortization For Continuing Operations DepreciationAndAmortizationForContinuingOperations	18400000	USD
CY2019	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1500000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	177500000	USD
CY2018	us-gaap	Health Care Organization Revenue Net Of Patient Service Revenue Provisions HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions	1662600000	USD
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	992900000	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	501300000	USD
CY2018	amed	Depreciation And Amortization For Continuing Operations DepreciationAndAmortizationForContinuingOperations	13300000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	155100000	USD
CY2020Q1	us-gaap	Health Care Organization Revenue Net Of Patient Service Revenue Provisions HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions	491700000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	31800000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.98
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.96
CY2020Q2	us-gaap	Health Care Organization Revenue Net Of Patient Service Revenue Provisions HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions	485000000.0	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	34700000	USD
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.07
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.04
CY2020Q3	us-gaap	Health Care Organization Revenue Net Of Patient Service Revenue Provisions HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions	544100000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	72000000.0	USD
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.20
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.16
CY2020Q4	us-gaap	Health Care Organization Revenue Net Of Patient Service Revenue Provisions HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions	550700000	USD
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	45100000	USD
CY2020Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.38
CY2020Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.36
CY2020	us-gaap	Health Care Organization Revenue Net Of Patient Service Revenue Provisions HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions	2071500000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	183600000	USD
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	5.64
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	5.52
CY2019Q1	us-gaap	Health Care Organization Revenue Net Of Patient Service Revenue Provisions HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions	467300000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	31300000	USD
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.98
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.95
CY2019Q4	us-gaap	Health Care Organization Revenue Net Of Patient Service Revenue Provisions HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions	500700000	USD
CY2019Q2	us-gaap	Health Care Organization Revenue Net Of Patient Service Revenue Provisions HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions	493000000.0	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	33700000	USD
CY2019Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.05
CY2019Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.02
CY2019Q3	us-gaap	Health Care Organization Revenue Net Of Patient Service Revenue Provisions HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions	494600000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	34100000	USD
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.06
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.03
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	27700000	USD
CY2019Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.86
CY2019Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.83
CY2019	us-gaap	Health Care Organization Revenue Net Of Patient Service Revenue Provisions HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions	1955600000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	126800000	USD
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.95
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.84

Files In Submission

Name	View Source	Status
0000896262-21-000045-index-headers.html	Edgar Link	pending
0000896262-21-000045-index.html	Edgar Link	pending
0000896262-21-000045.txt	Edgar Link	pending
0000896262-21-000045-xbrl.zip	Edgar Link	pending
a202010-kexhibit1016.htm	Edgar Link	pending
a202010-kexhibit1026.htm	Edgar Link	pending
a202010-kexhibit211.htm	Edgar Link	pending
a202010-kexhibit231.htm	Edgar Link	pending
a202010-kexhibit311.htm	Edgar Link	pending
a202010-kexhibit312.htm	Edgar Link	pending
a202010-kexhibit321.htm	Edgar Link	pending
a202010-kexhibit322.htm	Edgar Link	pending
amed-20201231.htm	Edgar Link	pending
amed-20201231.xsd	Edgar Link	pending
amed-20201231_cal.xml	Edgar Link	unprocessable
amed-20201231_def.xml	Edgar Link	unprocessable
amed-20201231_g1.jpg	Edgar Link	pending
amed-20201231_g2.jpg	Edgar Link	pending
amed-20201231_htm.xml	Edgar Link	completed
amed-20201231_lab.xml	Edgar Link	unprocessable
amed-20201231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AMED
AMEDISYS INC Stock $amed

2020 Q4 Form 10-K Financial Statement

#000089626221000045 Filed on February 25, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMED AMEDISYS INC Stock $amed

2020 Q4 Form 10-K Financial Statement

#000089626221000045 Filed on February 25, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMED
AMEDISYS INC Stock $amed